‘A watershed moment’: HeartFlow praises new chest pain guidelines

Michael Walter | | Cardiovascular Business | Computed Tomography

HeartFlow, a California-based healthcare technology company focused on cardiac care, has shared its support of new guidelines from the American College of Cardiology and American Heart Association that detail the evaluation and diagnosis of chest pain.

HeartFlow noted that the new guidelines recognized its AI-powered HeartFlow FFRCT Analysis solution as a “reasonable,” “effective” treatment option for diagnosing coronary artery disease (CAD). The document also emphasized the importance of coronary CT angiography (CTA) as a first-line test for valuating CAD patients, an update sure to get more clinicians interested in that modality than ever before.

“Since inception, HeartFlow has been committed to producing comprehensive clinical evidence to substantiate the diagnostic accuracy, safety, efficacy, cost-effectiveness, and utility of our technology and we are delighted to see the clinical recommendations for its use through these updated guidelines,” John H. Stevens, MD, president, CEO and co-founder of HeartFlow, said in a prepared statement. “We anticipate the guidelines will translate to stronger adoption of our precision heart care technology and look forward to supporting an expanded patient and physician population that can benefit from the advanced diagnostic capability it provides.”

“This evolution of the guidelines, and its impact to patients and clinicians, marks a watershed moment in CAD diagnosis and treatment,” Campbell Rogers, MD, chief medical officer of HeartFlow, said in the same statement. “The recommendations crystallize coronary CTA as the ascendent front-line test to diagnose CAD accurately and indicate the critical role our HeartFlow Analysis should play in making patient-specific decisions about when to go to the catheterization lab and what revascularization treatment strategies to employ.”

 

Related Cardiac CT Content:

VIDEO: Cardiac CT now recommended as a front line chest pain assessment tool — Interview with Leslee Shaw, PhD

VIDEO: Office-based cardiac CT and FFR-CT offer a new business model

‘A watershed moment’: HeartFlow praises new chest pain guidelines

Imaging group says new guidelines for chest pain contain some ‘troubling recommendations’

American Society of Nuclear Cardiology says AHA/ACC chest pain guidelines miss the mark

Expert panel recommends coronary CTA as first choice when evaluating for stable CAD

Find more ACC conference news and video

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Cardiologists, radiologists and surgeons share ‘landmark’ document on assessing prosthetic heart valves with CT
AI model gets helpful heart assessments out of nongated CT scans
ACC backs AMA resolution to boost lung cancer and heart disease screenings in smokers with low-dose CT scans
A closer look at GE HealthCare's new affordable cardiac CT scanner
Imaging for chest pain: CT- and ICA-first strategies linked to similar long-term health status
CCTA shows colchicine's impact on atherosclerosis progression

Around the web

Health Exec
Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging
Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business
U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.